FDA Accepts Filing of New Drug Application (NDA) for Yaupon Therapeutics Inc.'s Proprietary Gel Formulation of Mechlorethamine Hydrochloride  
10/4/2011 8:46:14 AM

MALVERN, Pa.--(BUSINESS WIRE)--Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine). Yaupon is seeking U.S. marketing approval of its mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, the most common type of Cutaneous T-Cell Lymphoma (CTCL).